Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).
about
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspectiveWork disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA studyEffectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid ArthritisObservational studies: a valuable source for data on the true value of RA therapies.Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study.Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpiCertolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007New and emerging therapies for the treatment of rheumatoid arthritis.Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort.Tocilizumab: is there life beyond anti-TNF blockade?The value of early intervention in RA--a window of opportunity.Similar biotherapeutic products: overview and reflections.Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.MicroRNA-15b Modulates Molecular Mediators of Blood Induced Arthropathy in Hemophilia Mice.Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment.Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy.Work productivity loss in early arthritis during the first 3 years of disease: a study from a French National Multicenter Cohort.Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s.Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.The economic burden of rheumatoid arthritis: beyond health care costs
P2860
Q26770099-793BF4BE-A0A8-4B05-B4F2-6B4005594F4FQ33540305-71E46459-AB9F-4058-A52A-76EF27348B81Q33652800-F5046D91-8137-4C26-BDC6-722C278368ACQ33779130-56E38701-C269-4158-AD38-0EC7CF0DACB4Q34114195-490D98C0-6494-4DE8-85F9-F91A5C7A5B0FQ34249182-A1658B11-9207-40F9-83D2-E783A3333D80Q34283216-6C2C1BB9-6CA8-4304-AD88-B2D2EBE06A2EQ35351313-5700BF60-4243-4C91-8AED-36C60A1C61ABQ36171750-9D041D9F-FD80-4AD7-93D5-128C5B6E91D8Q37358229-63CF6641-29DC-40CA-BDF2-143DE9D95878Q37595991-8252CCC8-DF52-47F0-8303-25B5C8BB060CQ37832771-1246662D-4494-4F0F-A7D2-379DCC1DD6DCQ37847069-D2E64186-B2E3-4915-9449-0C3D089F2E33Q38067449-C8F0C4E4-4F6F-4540-AF97-741C2B2946E1Q38306139-A08DA96B-D8E4-4D1A-B9A1-57033BC5BFB8Q38845478-A62D8064-E574-4DE4-A201-CB05D91C383FQ39821943-525098A5-1721-4861-9C5C-CD9403D8E0C0Q39857350-A47F16A4-80F8-414B-9491-E5233EE6373AQ44790776-72B8C3BB-FDF1-4EB9-8265-8DB7C22B9694Q45731720-ACC5A682-346B-4875-AE1E-4D7436792C39Q50624218-AC74D382-70E7-4117-A957-BFAA04782A60Q50661536-BDB57D9E-DE05-4D32-9B11-9D86B91EA29AQ51132948-C4A9C627-5166-401E-9BCB-25C746E08491Q51458036-373E399B-25F3-4DB8-A433-964990696AF9Q53441582-2D543741-7BCB-420A-9146-D5DD01447C31Q58025187-1C6EDF44-BAFD-44FE-A0EC-417BF0B65FA2
P2860
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Patients with rheumatoid arthr ...... a population-based registry).
@ast
Patients with rheumatoid arthr ...... a population-based registry).
@en
type
label
Patients with rheumatoid arthr ...... a population-based registry).
@ast
Patients with rheumatoid arthr ...... a population-based registry).
@en
prefLabel
Patients with rheumatoid arthr ...... a population-based registry).
@ast
Patients with rheumatoid arthr ...... a population-based registry).
@en
P2093
P356
P1476
Patients with rheumatoid arthr ...... m a population-based registry)
@en
P2093
C Cullinane-Carli
J Augustsson
R F van Vollenhoven
P304
P356
10.1136/ARD.2009.108035
P407
P577
2010-01-01T00:00:00Z